Avalo Therapeutics Inc. (NASDAQ: AVTX)
$6.2100
-0.3100 ( -4.90% ) 52.1K
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Market Data
Open
$6.2100
Previous close
$6.5200
Volume
52.1K
Market cap
$65.71M
Day range
$6.2350 - $6.9000
52 week range
$3.9501 - $34.4600
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| s-3 | Registration statements | 6 | Jun 06, 2024 |
| 8-k/a | 8K-related | 16 | Jun 03, 2024 |
| 8-k | 8K-related | 13 | May 23, 2024 |
| sc | Insider transactions | 1 | May 13, 2024 |
| 10-q | Quarterly Reports | 75 | May 13, 2024 |
| 8-k | 8K-related | 15 | May 13, 2024 |
| sc | Insider transactions | 3 | Apr 23, 2024 |
| d | Other | 1 | Apr 09, 2024 |
| sc | Insider transactions | 1 | Apr 05, 2024 |
| 3 | Insider transactions | 2 | Apr 03, 2024 |